Med Check: Updates to Clozapine REMS, Weekly Treatment for OUD, and More

2021 ◽  
Vol 56 (9) ◽  
Author(s):  
Terri D’Arrigo
Keyword(s):  
Weekly Treatment

scholarly journals In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Michele Dei Cas ◽  
Jessica Rizzo ◽  
Mariangela Scavone ◽  
Eti Femia ◽  
Gian Marco Podda ◽  
...  
Keyword(s):  
Oral Administration ◽  
Whole Blood ◽  
Serum Levels ◽  
Reversed Phase ◽  
Weekly Treatment ◽  
Low Dose Aspirin ◽  
Liquid Chromatography Tandem Mass ◽  
Enteric Coated

AbstractLow-dose aspirin (ASA) is used to prevent cardiovascular events. The most commonly used formulation is enteric-coated ASA (EC-ASA) that may be absorbed more slowly and less efficiently in some patients. To uncover these “non-responders” patients, the availability of proper analytical methods is pivotal in order to study the pharmacodynamics, the pharmacokinetics and the metabolic fate of ASA. We validated a high-throughput, isocratic reversed-phase, negative MRM, LC–MS/MS method useful for measuring circulating ASA and salicylic acid (SA) in blood and plasma. ASA-d4 and SA-d4 were used as internal standards. The method was applied to evaluate: (a) the "in vitro" ASA degradation by esterases in whole blood and plasma, as a function of time and concentration; (b) the "in vivo" kinetics of ASA and SA after 7 days of oral administration of EC-ASA or plain-ASA (100 mg) in healthy volunteers (three men and three women, 37–63 years). Parameters of esterases activity were Vmax 6.5 ± 1.9 and Km 147.5 ± 64.4 in plasma, and Vmax 108.1 ± 20.8 and Km 803.2 ± 170.7 in whole blood. After oral administration of the two formulations, tmax varied between 3 and 6 h for EC-ASA and between 0.5 and 1.0 h for plain-ASA. Higher between-subjects variability was seen after EC-ASA, and one subject had a delayed absorption over eight hours. Plasma AUC was 725.5 (89.8–1222) for EC-ASA, and 823.1(624–1196) ng h/mL (median, 25–75% CI) for plain ASA. After the weekly treatment, serum levels of TxB2 were very low (< 10 ng/mL at 24 h from the drug intake) in all the studied subjects, regardless of the formulation or the tmax. This method proved to be suitable for studies on aspirin responsiveness.

scholarly journals Glycol chitosan-based tacrolimus-loaded nanomicelle therapy ameliorates lupus nephritis

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Chang Seong Kim ◽  
Ansuja Pulickal Mathew ◽  
Arathy Vasukutty ◽  
Saji Uthaman ◽  
Soo Yeon Joo ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Kidney Injury ◽  
Therapeutic Modality ◽  
Drug Adherence ◽  
Glycol Chitosan ◽  
Inflammatory Gene Expression ◽  
Hydrophobically Modified ◽  
Intravenous Treatment ◽  
Weekly Treatment ◽  
Tgf Β1

Abstract Background Recently, we developed hydrophobically modified glycol chitosan (HGC) nanomicelles loaded with tacrolimus (TAC) (HGC-TAC) for the targeted renal delivery of TAC. Herein, we determined whether the administration of the HGC-TAC nanomicelles decreases kidney injury in a model of lupus nephritis. Lupus-prone female MRL/lpr mice were randomly assigned into three groups that received intravenous administration of either vehicle control, an equivalent dose of TAC, or HGC-TAC (0.5 mg/kg TAC) weekly for 8 weeks. Age-matched MRL/MpJ mice without Faslpr mutation were also treated with HGC vehicle and used as healthy controls. Results Weekly intravenous treatment with HGC-TAC significantly reduced genetically attributable lupus activity in lupus nephritis-positive mice. In addition, HGC-TAC treatment mitigated renal dysfunction, proteinuria, and histological injury, including glomerular proliferative lesions and tubulointerstitial infiltration. Furthermore, HGC-TAC treatment reduced renal inflammation and inflammatory gene expression and ameliorated increased apoptosis and glomerular fibrosis. Moreover, HGC-TAC administration regulated renal injury via the TGF-β1/MAPK/NF-κB signaling pathway. These renoprotective effects of HGC-TAC treatment were more potent in lupus mice compared to those of TAC treatment alone. Conclusion Our study indicates that weekly treatment with the HGC-TAC nanomicelles reduces kidney injury resulting from lupus nephritis by preventing inflammation, fibrosis, and apoptosis. This advantage of a new therapeutic modality using kidney-targeted HGC-TAC nanocarriers may improve drug adherence and provide treatment efficacy in lupus nephritis mice.

Once-weekly treatment with oral ketoconazole for superficial fungal infections

1993 ◽  
Vol 28 (1) ◽  
pp. 126-127 ◽  
Author(s):  
Rina Segal ◽  
Akiva Trattner ◽  
Isaac Alteras ◽  
Arie Ingber ◽  
Michael David ◽  
...  
Keyword(s):  
Fungal Infections ◽  
Weekly Treatment

scholarly journals CANOMAD responding to weekly treatment with intravenous immunoglobulin (IVIg)

2014 ◽  
Vol 2014 (apr10 1) ◽  
pp. bcr2013202545-bcr2013202545 ◽  
Author(s):  
M. Krenn ◽  
G. Keir ◽  
U. C. Wieshmann
Keyword(s):  
Intravenous Immunoglobulin ◽  
Weekly Treatment

Suspected bisphosphate-related osteonecrosis of the jaw in a cat being treated with alendronate for idiopathic hypercalcaemia

2019 ◽  
Vol 7 (3) ◽  
pp. e000798
Author(s):  
Emma Rogers-Smith ◽  
Nat Whitley ◽  
Clive Elwood ◽  
David Reese ◽  
Paula Wong
Keyword(s):  
Dental Treatment ◽  
Abdominal Mass ◽  
Clinical History ◽  
Osteonecrosis Of The Jaw ◽  
Bisphosphonate Therapy ◽  
Radiographic Appearance ◽  
Weekly Treatment ◽  
Facial Swelling ◽  
Ct Evaluation

An 8-year-old female neutered domestic shorthair diagnosed with idiopathic hypercalcaemia and undergoing weekly treatment with alendronate presented to Davies Veterinary Specialists for progressive facial swelling and discomfort 12 months after commencement of bisphosphonate treatment. Progression of the pathology was documented through clinical history from the referring practice when the patient underwent dental treatment with dental radiographs and then subsequently CT evaluation of the lesions. Proliferative and lytic, multifocal bony changes to the jaw, with a strikingly similar radiographic appearance to that seen in humans suffering from bisphosphonate-related osteonecrosis of the jaw (BRONJ), were seen. BRONJ is a well-recognised side effect of bisphosphonate therapy in people undergoing bisphosphonate therapy for the management of malignant hypercalcaemia. The cat was eventually euthanised due to the development of an abdominal mass and declining quality of life.

scholarly journals P2.01-49 Comparision of Radiotheraphy Concurrent Weekly Treatment in Locally Advanced Unresectable Non Small Cell Lung Cancer

2018 ◽  
Vol 13 (10) ◽  
pp. S683-S684
Author(s):  
N. Akdeniz ◽  
M.A. Kaplan ◽  
Z. Urakci ◽  
M. Kucukoner ◽  
O. Karhan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Weekly Treatment

scholarly journals A Reversible Albumin-Binding Growth Hormone Derivative is Well Tolerated and Possesses a Potential Once-Weekly Treatment Profile

2014 ◽  
Vol 99 (10) ◽  
pp. E1819-E1829 ◽  
Author(s):  
Michael Højby Rasmussen ◽  
Minna W. Brændholt Olsen ◽  
Lene Alifrangis ◽  
Søren Klim ◽  
Mette Suntum
Keyword(s):  
Growth Hormone ◽  
Human Growth ◽  
Albumin Binding ◽  
Local Tolerability ◽  
Gh Treatment ◽  
Double Blind ◽  
Weekly Treatment ◽  
Relevant Dose ◽  
Present Trial ◽  
Male Subjects

Abstract Context: Human growth hormone (hGH) replacement therapy currently requires daily sc injections for years/lifetime, which may be both inconvenient and distressing for patients. NNC0195–0092 is a novel hGH derivative intended for once-weekly treatment of GH deficiency. A noncovalent albumin binding moiety is attached to the hGH backbone. Clearance is reduced as a consequence of a reversible binding to circulating serum albumin, which prolongs the pharmacodynamic (PD) effect. Objective: To evaluate safety, local tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single dose (SD) and multiple doses (MD) of NNC0195–0092. Setting and Design: Randomized, single-center, placebo-controlled, double-blind, SD/MD, dose-escalation trial of 105 healthy male subjects. NNC0195–0092 sc administration: Five cohorts of eight subjects received one dose of NNC0195–0092 (0.01–0.32 mg/kg) (n = 6) or placebo (n = 2). Sixteen subjects (equal numbers of Japanese and non-Asian) received once-weekly doses of NNC0195–0092 (0.02–0.24 mg/kg; n=12) or placebo (n=4) for 4 weeks. Blood samples were drawn for assessment of safety, PK, IGF-1, and IGF binding protein 3 profiles and anti-drug antibodies. Results: SD and MD of NNC0195–0092 were well tolerated at all dose levels. No safety concerns or local tolerability issues were identified. A dose-dependent IGF-1 response was observed. IGF-1 profiles suggest that NNC0195–0092 may be suitable for once-weekly dosing, with a clinically relevant dose ≤0.08 mg/kg/week. No differences in PK and PD were observed between Japanese and non-Asian subjects. Conclusions: SD and MD of NNC0195–0092 administered to healthy Japanese and non-Asian male subjects were well tolerated at all doses. The present trial suggests that NNC0195–0092 has the potential for an efficacious, well-tolerated, once-weekly GH treatment.

scholarly journals Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment

2018 ◽  
Vol 62 (11) ◽  
Author(s):  
Omamah Alfarisi ◽  
Vidya Mave ◽  
Sanjay Gaikwad ◽  
Tushar Sahasrabudhe ◽  
Geetha Ramachandran ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Clinical Outcomes ◽  
Geometric Mean ◽  
Univariate Analysis ◽  
Female Gender ◽  
Fixed Dose ◽  
Cox Models ◽  
Drug Concentrations ◽  
Weekly Treatment ◽  
Culture Conversion

ABSTRACT Diabetes mellitus (DM) and tuberculosis (TB) are two common diseases with increasing geographic overlap and clinical interactions. The effect of DM and hemoglobin A1c (HbA1c) values on the pharmacokinetics (PK) and pharmacodynamics (PD) of anti-TB drugs remains poorly characterized. Newly diagnosed TB patients with and without DM starting fixed-dose, thrice-weekly treatment underwent sampling for PK assessments (predose and 0.5, 2, and 6 h postdose) during the intensive and continuation phases of treatment. The effect of DM and HbA1c values on the maximum concentration (Cmax) of rifampin, isoniazid, and pyrazinamide and the association between drug concentrations and microbiologic and clinical outcomes were assessed. Of 243 patients, 101 had DM. Univariate analysis showed significant reductions in the Cmax of pyrazinamide and isoniazid (but not rifampin) with DM or increasing HbA1c values. After adjusting for age, sex, and weight, DM was associated only with reduced pyrazinamide concentrations (adjusted geometric mean ratio = 0.74, P = 0.03). In adjusted Cox models, female gender (adjusted hazards ratio [aHR] = 1.75, P = 0.001), a lower smear grade with the Xpert assay (aHR = 1.40, P < 0.001), and the pyrazinamide Cmax (aHR = 0.99, P = 0.006) were independent predictors of sputum culture conversion to negative. Higher isoniazid or rifampin concentrations were associated with a faster time to culture conversion in patients with DM only. A pyrazinamide Cmax above the therapeutic target was associated with higher unfavorable outcomes (treatment failure, relapse, death) (odds ratio = 1.92, P = 0.04). DM and higher HbA1c values increased the risk of not achieving therapeutic targets for pyrazinamide (but not rifampin or isoniazid). Higher pyrazinamide concentrations, though, were associated with worse microbiologic and clinical outcomes. DM status also appeared to influence PK-PD relationships for isoniazid and rifampin.

Sign in / Sign up

Export Citation Format

Share Document